Recall Register

Drug recall: Aripiprazole Tablets, USP, 10 mg, 30-count bottles, Rx only, Manufactured by: Alken Laboratories Ltd., INDIA…

Class II FDA enforcement event 97511. Recall start date: . Status in the FDA record: Ongoing.

Reason for recall, in the words of FDA

Superpotent drug

Class II, in the words of FDA

a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote

Ascend Laboratories, LLC started this drug recall on 28 Aug 2025. The firm address in the FDA record is in Bedminster, NJ. FDA put the recall in Class II. FDA event 97511 has 1 product record. The first FDA enforcement report date is 24 Sep 2025. The record gives the status Ongoing.

It is important to note that most of the time recall classifications are determined after the recalling firm provides all of the information needed to determine the risk posed to public health. The classification and posting in the FDA Enforcement Report should not be seen as an expansion or change to a firm’s voluntary public warning.

FDA publishes these words. Source: FDA, Enforcement Reports, Important Note, read on . openFDA export of .

Distribution

In the words of FDA.

Nationwide in the USA.

Recalling firm

Ascend Laboratories, LLC, Bedminster, NJ.

Recalling firm: The firm that the FDA record names for a recall.

FDA records how the recall started: Voluntary: Firm initiated.

Products

1 product record in the event.

FDA event 97511: product records
Recall numberProductQuantityClassStatusReport date
D-0645-2025Aripiprazole Tablets, USP, 10 mg, 30-count bottles, Rx only, Manufactured by: Alken Laboratories Ltd., INDIA; Distributed by: Ascend Laboratories, LLC, Parsippany, NJ 07054. NDC: 67877-432-032,256 bottlesClass IIOngoing24 Sep 2025

openFDA, about the status: FDA does not update the status of a recall after the recall has been classified according to its level of hazard. As such, the status of a recall (open, completed, or terminated) will remain unchanged after published in the Enforcement Reports. Source: openFDA, Drug Recall Enforcement Reports, Disclaimer.

Enforcement report: The FDA publication that lists recalls. It has one record for each product of a recall.

Enforcement event: All the product records that have one FDA event number. This site shows one event on one page.

Class II: The middle of the three FDA recall classes.

The event in context

Drug events that started in 2025
322
Share of these events in Class II
79%
Product records in this event
1Median of the firm: 1
Events of the firm on the register
36

Other events of the firm

Other FDA enforcement events of Ascend Laboratories, LLC
InitiatedProduct (first record)TypeClassRecords
16 Jul 2026Dabigatran Etexilate Capsules, 150 mg, 60-count (6x10) blister pack further packaged in a carton, Rx only, Manufactured DrugClass III3
8 Jul 2026Amlodipine and Olmesartan Medoxomil Tablets, 10 mg/20 mg, 30 Tablets per bottle, Rx Only, Manufactured by: Alkem LaboratDrugClass II1
30 Jun 2026Dabigatran etexilate Capsules, 110 mg, 60-count carton (6x10), Rx Only, Manufactured by: Alkem Laboratories, Mumbai, INDDrugClass III2
1 Jun 2026Minocycline Hydrochloride Extended-Release Tablets, USP, 115 mg, 30-count bottle, Rx Only, Manufactured by: Alkem LaboraDrugClass II1
5 May 2026Amlodipine and Olmesartan Medoxomil Tablets, 5mg/40mg, Rx Only, 30-count bottle, Manufactured by: Alkem Laboratories LtdDrugClass II1
27 Apr 2026Ascend Laboratories, LLC, Metoprolol Succinate Extended-Release Tablets, USP, 25 mg* Rx Only, Manufactured by: Alkem LabDrugClass II1
19 Sep 2025Atorvastatin Calcium Tablets USP, 10 mg, Rx Only a) 90-count bottle (NDC 67877-511-90), b). 500-count bottle (NDC 67877-DrugClass II4
21 Jul 2025Amlodipine and Olmesartan Medoxomil Tablets, 5 mg/ 40 mg, 30-count bottle, Rx Only, Manufactured by: Alkem Laboratories DrugClass II1
9 Jul 2025Rizatriptan Benzoate Tablets, USP, 5 mg, 18 (3x6) Unit Dose Tablets, Rx Only, Manufactured by: Alkem Laboratories Ltd., DrugClass II2
23 May 2025Cephalexin for Oral Suspension, USP, 125 mg per 5 mL, 100 mL (when mixed), Rx Only, Manufactured by: Alkem Laboratories DrugClass II2

Ascend Laboratories, LLC: all 36 events

Official channels

Cite this page

Recall Register. FDA enforcement event 97511. https://recallregister.com/fda/ii/97511/. Source: openFDA enforcement reports. Data through .

Sources

Source
openFDA drug enforcement reports
Licence
CC0 1.0
Export date
28 Sep 2026
Newest FDA report date on the register
23 Sep 2026

FDA has one record for each product. This site puts the records with the same event number on one page. The class of the event is the highest class of its records. How the register is made. Report an error.

Questions

Where was the product distributed?
The FDA record gives this distribution: Nationwide in the USA.
What quantity of product is in FDA event 97511?
The FDA record gives this quantity: 2,256 bottles
How did the recall start?
The FDA record says: Voluntary: Firm initiated
How many drug recalls of 2025 have the same class?
79% of the 322 drug events that started in 2025 are in Class II.